Roche announced that it has received FDA approval for expanded use of its PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Coc...
Revolution Medicines, Inc., a global commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patie...
Immuneering Corporation, a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, shared comments followi...
Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced two major clinical mi...
Lexicon Pharmaceuticals, Inc. announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achiev...
SciSparc Ltd.(“Company” or “SciSparc”), announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Lakefront Biotherapeutics NV announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the ...
Qosina, a global supplier of single-use components for the medical device and life sciences industries, today announced the launch of Qosina Regulatory S...
As breast imaging continues to evolve toward more quantitative and patient-centred approaches, QT Imaging is developing a three-dimensional ultraso...
Johnson & Johnson announced that the European Commission (EC) has approved an indication extension for TECVAYLI®(teclistamab) in combination with...
Milestone® Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medi...
Orum Therapeutics(“Orum” or the “Company”), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), ...
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by po...
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to redu...
© 2026 Biopharma Boardroom. All Rights Reserved.
